CA3076750A1 - Stable cannabinoid compositions - Google Patents

Stable cannabinoid compositions Download PDF

Info

Publication number
CA3076750A1
CA3076750A1 CA3076750A CA3076750A CA3076750A1 CA 3076750 A1 CA3076750 A1 CA 3076750A1 CA 3076750 A CA3076750 A CA 3076750A CA 3076750 A CA3076750 A CA 3076750A CA 3076750 A1 CA3076750 A1 CA 3076750A1
Authority
CA
Canada
Prior art keywords
aqueous
corresponds
alkoxylated solvent
temperature
alkoxylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3076750A
Other languages
English (en)
French (fr)
Inventor
Ilse Knoller
Thomas SOWIK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sino German M&a Service GmbH
Original Assignee
Sino German M&a Service GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sino German M&a Service GmbH filed Critical Sino German M&a Service GmbH
Publication of CA3076750A1 publication Critical patent/CA3076750A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3076750A 2017-07-07 2018-07-06 Stable cannabinoid compositions Pending CA3076750A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17180380.2A EP3424493A1 (en) 2017-07-07 2017-07-07 Stable cannabinoid compositions
EP17180380.2 2017-07-07
PCT/EP2018/068452 WO2019008179A1 (en) 2017-07-07 2018-07-06 STABLE CANNABINOID COMPOSITIONS

Publications (1)

Publication Number Publication Date
CA3076750A1 true CA3076750A1 (en) 2019-01-10

Family

ID=59315425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3076750A Pending CA3076750A1 (en) 2017-07-07 2018-07-06 Stable cannabinoid compositions

Country Status (10)

Country Link
US (1) US11752126B2 (https=)
EP (2) EP3424493A1 (https=)
JP (1) JP7186222B2 (https=)
KR (1) KR102680507B1 (https=)
CN (2) CN115120558A (https=)
AU (1) AU2018296679B2 (https=)
CA (1) CA3076750A1 (https=)
EA (1) EA202090177A1 (https=)
IL (1) IL271892B2 (https=)
WO (1) WO2019008179A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230000770A1 (en) * 2019-12-06 2023-01-05 Hanyi Biotechnology (Beijing) Co., Ltd Cannabinoid nanomicelle preparation and method for preparing same

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4466002A1 (de) 2022-01-20 2024-11-27 Solmic Biotech GmbH Topisch anwendbare zusammensetzung enthaltend solubilisate lipophiler wirkstoffe
DE202022000150U1 (de) 2022-01-20 2022-07-07 Solmic Bio Tech Gmbh Maske für medizinische oder kosmetische Zwecke mit mizellierten Extrakten
EP4275694A1 (de) 2022-05-13 2023-11-15 Solmic Biotech GmbH Verwendung von solubilisaten in erzeugnissen zur topischen anwendung
CN117986017B (zh) * 2023-11-27 2025-11-21 陕西师范大学 一种（Sm2-aYa）Ba4CuBiO10纳米粉体及用其改善单畴SmBCO超导块材性能的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270426T3 (es) 1994-03-18 2007-04-01 Supernus Pharmaceuticals, Inc. Sistema de suministros de farmacos emulsionados.
MXPA01011981A (es) * 1999-05-24 2003-09-04 Sonus Pharma Inc Vehiculo de emulsion para farmacos poco solubles.
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
ES2283756T3 (es) * 2002-03-01 2007-11-01 Novagali Pharma Sa Sistemas autoemulsionantes de administracion de farmaco para taxoides.
US20080045559A1 (en) * 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US20100235972A1 (en) 2005-07-28 2010-09-23 Guasch Michael N Fuel repellent compositions, fabrics and articles
US7402325B2 (en) * 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
TWI392507B (zh) * 2006-10-20 2013-04-11 Solvay Pharm Bv 包埋的膠束奈米顆粒
WO2008046905A1 (en) * 2006-10-20 2008-04-24 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
PL2352497T3 (pl) * 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
US20120088829A1 (en) * 2010-09-29 2012-04-12 MyCell Holdings Limited Formulations of Ubiquinol and Resveratrol Esters
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
WO2014165672A1 (en) * 2013-04-06 2014-10-09 Igdrasol, Inc. Nanoparticle therapeutic agents, their formulations, and methods of their use
US9861611B2 (en) * 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US20170119660A1 (en) * 2015-10-29 2017-05-04 Solubest Ltd Pharmaceutical compositions for transmucosal delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230000770A1 (en) * 2019-12-06 2023-01-05 Hanyi Biotechnology (Beijing) Co., Ltd Cannabinoid nanomicelle preparation and method for preparing same

Also Published As

Publication number Publication date
JP7186222B2 (ja) 2022-12-08
EP3675825A1 (en) 2020-07-08
AU2018296679A1 (en) 2020-02-20
IL271892B1 (en) 2023-04-01
US11752126B2 (en) 2023-09-12
IL271892B2 (en) 2023-08-01
IL271892A (en) 2020-02-27
JP2020527170A (ja) 2020-09-03
KR20200037247A (ko) 2020-04-08
AU2018296679B2 (en) 2024-07-25
CN111246844A (zh) 2020-06-05
US20200237713A1 (en) 2020-07-30
EA202090177A1 (ru) 2020-06-05
KR102680507B1 (ko) 2024-07-01
CN115120558A (zh) 2022-09-30
WO2019008179A1 (en) 2019-01-10
EP3424493A1 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
AU2018296678B2 (en) Stable cannabinoid compositions
AU2018296679B2 (en) Stable cannabinoid compositions
JP4463551B2 (ja) 改良された生物学的利用能を有する製剤における高分子量で親油性で経口摂取可能な生物活性物質
US4572915A (en) Clear micellized solutions of fat soluble essential nutrients
JP3103430B2 (ja) 脂溶性抗酸化剤混合物
KR20080108262A (ko) 물질의 용해, 분산 및 안정을 위한 방법, 상기 방법에 따라제조된 제품 및 상기 제품의 이용
MXPA02008295A (es) Soluciones de acido ascorbico estabilizado; su uso; proceso para su obtencion; y formaciones que las contienen.
US20050238675A1 (en) Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
US20120321604A1 (en) Carrier comprising non-neutralised tocopheryl phosphate
US20220370379A1 (en) Cannabinoid-containing additive and method therefor
KR20140071913A (ko) 식품 조성물 및 이를 포함하는 연질 캡슐
Papas Vitamin E TPGS and its applications in nutraceuticals
US20230058895A1 (en) Physiologically acceptable eutectic mixtures of cannabidiol
EA044031B1 (ru) Стабильная композиция каннабиноида
RU2303036C2 (ru) Солюбилизат из аскорбиновой кислоты и эмульгатора, смесь солюбилизатов, способ изготовления солюбилизата и его применение (варианты)
KR20240137658A (ko) 방부 효과를 부여한 나노에멀션
US20210353588A1 (en) Dietary supplement composition comprising of cannabis sativa extracts
JP7752233B2 (ja) 親油性化合物の改善された経口バイオアベイラビリティを有する自己乳化薬物送達配合物
RS51028B (sr) Postupak za solubilizaciju, disperziju i stabilizaciju supstanci, proizvodi proizvedeni po ovom postupku kao i upotreba istih

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230704

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240808

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241209

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20250131

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250131

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250220

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250617

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250617

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250720

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250720